Previous Article | Next Article 
Infection and Immunity, May 2001, p. 3224-3231, Vol. 69, No. 5
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.3224-3231.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
C-Terminal Invariable Domain of VlsE Is Immunodominant but
Its Antigenicity Is Scarcely Conserved among Strains of Lyme
Disease Spirochetes
Fang Ting
Liang,
Lisa C.
Bowers, and
Mario T.
Philipp*
Department of Parasitology, Tulane Regional Primate
Research Center, Tulane University Health Sciences Center,
Covington, Louisiana 70433
Received 18 December 2000/Returned for modification 5 February
2001/Accepted 14 February 2001
 |
ABSTRACT |
VlsE, the variable surface antigen of Borrelia
burgdorferi, contains two invariable domains located at the
amino and carboxyl terminal ends, respectively, and a central variable
domain. In this study, both immunogenicity and antigenic conservation
of the C-terminal invariable domain were assessed. Mouse antiserum to a
51-mer synthetic peptide (Ct) which reproduced the entire sequence of
the C-terminal invariable domain of VlsE from B.
burgdorferi strain B31 was reacted on immunoblots with
whole-cell lysates extracted from spirochetes of 12 strains
from the B. burgdorferi sensu lato species complex. The
antiserum recognized only VlsE from strain B31, indicating that
epitopes of this domain differed among these strains. When Ct was used
as enzyme-linked immunosorbent assay (ELISA) antigen, all of the seven
monkeys and six mice that were infected with B31 spirochetes produced a
strong antibody response to this peptide, indicating that the
C-terminal invariable domain is immunodominant. None of 12 monkeys and only 11 of 26 mice that were infected with strains other
than B31 produced a detectable anti-Ct response, indicating a limited
antigenic conservation of this domain among these strains. Twenty-six
of 33 dogs that were experimentally infected by tick inoculation
were positive by the Ct ELISA, while only 5 of 18 serum samples from
dogs clinically diagnosed with Lyme disease contained detectable
anti-Ct antibody. Fifty-seven of 64 serum specimens that were collected
from American patients with Lyme disease were positive by the Ct ELISA,
while only 12 of 21 European samples contained detectable
anti-Ct antibody. In contrast, antibody to the more conserved
invariable region IR6 of VlsE was present in all of these
dog and human serum samples.
 |
INTRODUCTION |
All variable antigens, such
as the variant surface glycoprotein of the protozoan Trypanosoma
brucei (4, 5, 31), the variable major protein (Vmp)
of the spirochete Borrelia hermsii (23, 28),
pilin of the bacterium Neisseria gonorrhoeae
(11), the major surface protein 2 of the ehrlichia
Anaplasma marginale (8, 9, 24), and the
variable surface antigen (VlsE) of the Lyme disease spirochete
Borrelia burgdorferi (14, 32-34), are
immunodominant surface proteins which contain both variable and
invariable portions. In the variant surface glycoprotein, Vmp, pilin,
and major surface protein 2, immunodominance is contributed almost
exclusively by their variable portions (1, 3, 6-9, 27).
The latter are able to generate multiple serotypes for a given isolate,
and thus, these variable antigens have little value for serodiagnosis.
In contrast, VlsE contains several immunodominant invariable portions
(16, 17), which are likely the molecular basis for the
usefulness of this molecule in the serodiagnosis of Lyme disease (15, 18, 20, 21; R. Murphree, B. J. Biggerstaff, and B. J. B. Johnson, Abstr. 100th Gen. Meet. Am. Soc. Microbiol., abstr. V-10, p.
661, 2000).
VlsE has a predicted molecular mass of 34 kDa in the B31 strain of
B. burgdorferi sensu stricto (32). It contains
two invariable domains, one at the amino and the other at the carboxyl
terminus, which together encompass approximately one-half of the
molecule's length; there is, in addition, one central variable domain
(32). The latter contains six variable regions and six
invariable regions (IRs), named IR1 to
IR6 (16, 32). Regardless of their
antigenicity, the variable portions probably have no diagnostic value.
The six IRs remain unchanged during antigenic variation, and limited
sequence data indicate that they are conserved among B. burgdorferi sensu lato genospecies and strains (14, 16,
32). Both IR2 and IR6 not only are immunodominant but are also
antigenically conserved among the genospecies and strains of Lyme
disease spirochetes (16, 17, 20, 21). Immunodominance of
IR2 has been noted in selected host species, such
as mice and dogs, but not humans or monkeys (17, 21).
Thus, IR2 has no diagnostic value in human Lyme
disease. Although IR2 is immunodominant in dogs,
its diagnostic value is negligible (21). In contrast,
IR6, when adapted to a peptide-based
enzyme-linked immunosorbent assay (ELISA), has been shown to be a
highly sensitive and specific diagnostic reagent both for human and
canine Lyme disease (18, 20, 21). Like the six IRs, the
two invariable domains are also unchanged during antigenic variation
(32). It is not known if the sequences of these two
domains are conserved among the genospecies and strains of B. burgdorferi sensu lato since sequence data are available only for
B. burgdorferi sensu stricto B31 (32).
In the present study, immunogenicity of the C-terminal invariable
domain was assessed in four host species, namely monkeys, mice, dogs,
and humans. The antigenic conservation of this domain was investigated
among strains of B. burgdorferi sensu lato, and its
potential diagnostic application in both human and canine Lyme disease
was evaluated. Antibody to the C-terminal invariable domain of B. burgdorferi sensu stricto B31 was generated in mice and allowed to
react with immunoblots of whole-cell antigens extracted from 12 spirochetal strains that represented the three pathogenic genospecies
of B. burgdorferi sensu lato. To determine immunogenicity and further assess antigenic conservation of the C-terminal domain of
VlsE, serum specimens from monkeys and mice that were experimentally infected with different spirochetal strains were tested for antibody to
a synthetic peptide (Ct) that reproduced the sequence of the C-terminal
invariable domain of strain B31. To examine the potential diagnostic
value of the Ct peptide, sera from dogs that were either clinically
diagnosed with Lyme disease or experimentally infected with B. burgdorferi and from human patients with Lyme disease were also
tested for anti-Ct antibody levels.
 |
MATERIALS AND METHODS |
Spirochete strains.
B. burgdorferi sensu stricto
strains B31, Sh-2-82, NT1, JD1, and N40, Borrelia garinii
strains IP90, G1, G25, NBS23A, and NBS16, and Borrelia
afzelii strains J1 and P/Gau were cultivated in BSK-H medium
supplemented with 10% rabbit serum (Sigma Chemical Co., St. Louis,
Mo.). Spirochetes grown to stationary phase were used in this study.
Peptide synthesis and conjugation to biotin and KLH.
Two
peptides were prepared using the fluorenylmethoxycarbonyl
synthesis protocol (2). The Ct
peptide (CEGAIKGAAESAVRKVLGAITGLIGDAVSSGLRKVGDSVKASKET PPALNK)
reproduced the sequence of the C-terminal invariable domain of VlsE
from the B. burgdorferi clonal isolate B31-5A3
(32). The C6 peptide
(CMKKDDQIAAAMVLRGMAKDGQFALK) was synthesized based on
the IR6 sequence of VlsE cloned from B. garinii strain IP90 (16). The cysteine residue that
was included at the N terminus of each synthetic peptide was used as
the conjugation site. Conjugation to biotin or keyhole limpet
hemocyanin (KLH) was performed by the N-succinimidyl
maleimide carboxylate method. The maleimide reagent was from Molecular
Probes (Eugene, Oreg.), and the protocol suggested by the manufacturer
was followed.
Preparation of antibodies to peptides Ct and C6.
To generate antiserum to the Ct peptide, mice (6- to 8-week-old
C3H/HeN; Charles River Laboratories, Wilmington, Mass.) were given
three intraperitoneal injections at 3-week intervals of 100 µg of
Ct-KLH conjugate emulsified with MPL and TOM adjuvant (Sigma). Two
weeks after the last injection, the titer of antibody to the Ct peptide
was assessed by ELISA. To generate antibody to the
C6 peptide, 6-month-old New Zealand White rabbits
were given three subcutaneous doses at biweekly intervals of 200 µg of C6-KLH conjugate emulsified with Freund's
complete (first injection) or incomplete (remaining injections)
adjuvant. Ten days after the last injection, the antibody titer was
determined by the C6 ELISA.
Peptide-based ELISA.
Ninety-six-well ELISA plates were
coated with 100 µl per well of 4 µg of streptavidin (Pierce
Chemical Company, Rockford, Ill.)/ml in coating buffer (0.1 M carbonate
buffer, pH 9.2) and incubated at 4°C overnight. The remaining steps
were conducted in a rotatory shaker at room temperature. After two
3-min washes with 200 µl per well of phosphate-buffered saline (PBS)
containing 0.1% Tween 20 (pH 7.4) (PBS/T) at 200 rpm, 200 µl of 5 µg of biotinylated peptide (Ct or C6)/ml
dissolved in blocking solution (PBS/T supplemented with 5% nonfat dry
milk) was applied to each well. The plate was shaken at 200 rpm for
2 h. After three washes with PBS/T, 50 µl of mouse, monkey, dog,
or human serum diluted 1:200 with blocking solution was added to each
well. The plate was incubated at 200 rpm for 1 h and then washed
three times with PBS/T. Each well then received 100 µl of 0.5 µg of
goat anti-mouse immunoglobulin G (IgG) (heavy and light chain specific;
Sigma)/ml, 0.5 µg of goat anti-monkey IgG (
chain specific;
Kirkegaard & Perry Laboratories, Gaithersburg, Md.)/ml, 0.35 µg of
rabbit anti-dog IgG (heavy and light chain specific; Sigma)/ml,
or 0.1 µg of goat anti-human IgG (heavy and light chain specific;
Pierce)/ml, as appropriate. All additives were conjugated to
horseradish peroxidase and were dissolved in blocking solution. The
plate contents were incubated for 1 h while being shaken. After
three washes with PBS/T each for 3 min, the antigen-antibody reaction
was probed using the TMB microwell peroxidase substrate system
(Kirkegaard & Perry), and color was allowed to develop for 10 or 25 min
depending on the host species tested. The enzyme reaction was stopped
by the addition of 100 µl of 1 M
H3PO4. Optical density (OD)
was measured at 450 nm.
Immunoblotting.
Spirochetes grown to stationary phase were
harvested and washed twice with PBS by centrifugation at 8,000 × g for 20 min at 4°C. Washed spirochetes were suspended in
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis sample
buffer (125 mM Tris, 3% SDS, 5%
-mercaptoethanol, 10% glycerol,
0.01% bromophenol blue [pH 6.8]) at a concentration of 2.5 × 109 organisms per ml. The suspension was
incubated at 95°C for 5 min. Approximately 15 µl of such
preparation was applied to each sample lane of a 15-well minigel of
12% acrylamide. Resolved proteins were transferred onto nitrocellulose
in Towbin transfer buffer (30). The blot was shaken in
blocking solution for 2 h and then in the same solution
supplemented with either 1:500 diluted mouse anti-Ct serum or 1:1,000
diluted rabbit anti-C6 serum for an additional 2 h. After 3 washes with PBS/T, the blot was incubated in 2.0 µg
of goat anti-mouse IgG or anti-rabbit IgG horseradish peroxidase conjugate per ml for 1 h. After three washes with PBS/T, the blot was developed in PBS/T supplemented with 0.05% 4-chloro-naphthol, 0.015% H2O2, and 17% methanol.
Monkey serum specimens.
Serum specimens from 19 B. burgdorferi-infected rhesus monkeys (Macaca mulatta)
were used in this study. All of the animals were infected by the bite
of Ixodes scapularis nymphal ticks as described previously
(25). Seven animals were infected with B. burgdorferi sensu stricto strain B31 (animals L379, L452, L453, L457, L549, M021, and M581), six animals with strain JD1 (J200, J831,
K205, K216, K383, and L131), and six animals with NT1 (P285, P607,
R383, R454, R817, and V591). Blood samples were drawn at 8 to 10 weeks postinfection.
Mouse serum specimens.
Serum specimens from 32 B. burgdorferi-infected mice were examined. Eighteen mice were of the
C3H/HeN strain, and 14 were BALB/c. Animals of both strains were 6 to 8 weeks old. Six of the C3H mice were inoculated with B. burgdorferi strain B31 (mice 184, 191, 194, 196, 408, and 409) by
tick bite as described elsewhere (22). The remainder of
the C3H mice were needle inoculated with strains N40 (n = 2; Q53 and Q59), JD1 (n = 5; A77, A78, A79, A80, and
A81), and Sh-2-82 (n = 5; 219, 220, 228, 288, and 289).
Each mouse received 106 cultured spirochetes
administrated by subcutaneous injection. Blood samples were drawn at 4 weeks postinfection.
The BALB/c mice were infected with European strains of B. burgdorferi sensu lato by exposure to nymphal Ixodes
ricinus ticks, as described previously (10, 13).
These ticks were field collected either in Malonne, Belgium, or
Neuchâtel, Switzerland. Seven mice were exposed to ticks from
Neuchâtel (animals N57, N59, N63, N65, N67, N69, and N71) and the
remainder (animals M50, M52, M54, M56, M58, M62, and M64) were exposed
to Malonne ticks. Spirochetes were isolated from all of the mice that
were exposed to Neuchâtel ticks by ear punch biopsy culture.
Spirochete species were identified by a standard protocol described
previously (26). Spirochetes from Malonne ticks were not
classified. Blood samples were drawn at 4 weeks postinfection. Serum
specimens from mice infected with European spirochetes were kindly
provided by Lise Gern (University of Neuchâtel, Neuchâtel,
Switzerland) and by Vincent Weynants (GlaxoSmithKline Biologicals,
Rixensart, Belgium).
Dog serum specimens.
Thirty-three 6-week-old
specific-pathogen-free beagles of both sexes were infected by tick bite
as described previously (29). Serum specimens collected at
8 weeks postinoculation were used in this study. The specimens were
kindly provided by Reinhard Straubinger (Cornell University, Ithaca,
N.Y.).
Eighteen dog serum specimens (a gift from Richard Jacobson, Cornell
University) were also used in this study. These samples were originally
submitted for the serodiagnosis of Lyme disease and were collected from
dogs that were suspected to have Lyme disease. They were submitted from
different areas of the United States.
Ten control serum specimens (a gift from Amy Grooters, Louisiana State
University, Baton Rouge, La.) were collected from healthy dogs in
Louisiana. This panel of serum specimens was used to calibrate a cutoff
value for the ELISA. Lyme disease is not endemic in Louisiana, and the
dogs had no history of travel to areas of endemicity.
Human serum specimens.
Six panels of human serum specimens
were used in this study. Twenty samples (CDC1 to CDC20) were kindly
provided by Martin Schriefer (Centers for Disease Control and
Prevention, Fort Collins, Colo.). This serum panel was collected from
convalescent Lyme disease patients. Thirty-four serum specimens (T1 to
T34) were kindly provided by Allen Steere (Tufts University, Boston,
Mass.). These serum samples were collected from patients with late Lyme arthritis or neuroborreliosis. Ten serum specimens (NIH1 to NIH10) were
collected from patients with posttreatment Lyme disease syndrome (PTLDS) and were provided by Adriana Marques (National Institutes of
Health, Bethesda, Md.).
Two additional serum panels were from European patients. Thirteen serum
specimens (A1 to A13) were collected from Austrian patients with
acrodermatitis chronica atrophicans. The Austrian panel was kindly
provided by Elisabeth Aberer (University of Graz, Graz, Austria). Eight
samples (I1 to I8) were from Italian patients with acrodermatitis
chronica atrophicans, Lyme arthritis, or neuroborreliosis. The Italian
panel was kindly provided by Marina Cinco (Università Trieste,
Trieste, Italy).
Ten control human serum samples were collected from patients of a local
hospital in Louisiana. Lyme disease is not endemic in this area. This
serum panel was used to calibrate a cutoff value for the ELISA.
 |
RESULTS |
Epitopes of the C-terminal invariable domain differ among strains
of B. burgdorferi sensu lato.
Although the
C-terminal invariable domain of VlsE remains unchanged during antigenic
variation (32), it is not known if this sequence is
generally conserved among strains and genospecies of B. burgdorferi sensu lato. To address this issue, antibodies to Ct, a
peptide which reproduces the sequence of the C-terminal invariable
domain of strain B31, and to C6, which was
designed based on the sequence of IR6 of strain
IP90, were reacted with whole-cell extracts from 12 spirochetal strains
on immunoblots. These included B. burgdorferi sensu stricto
strains B31, Sh-2-82, NT1, JD1, and N40; B. garinii strains
IP90, G1, G25, NBS23A, and NBS16; and B. afzelii strains J1
and P/Gau. Anti-Ct antibody recognized only the VlsE antigen expressed
by strain B31 but not that expressed by the other 11 strains. This
result indicates that epitopes of the C-terminal domain are not
conserved among these strains (Fig. 1A).
Loss of the plasmid lp28-1, which carries the vlsE locus, or
lack of VlsE expression in vitro could not explain absence of
reactivity, as the 12 strain isolates that were used in this experiment
expressed an antigen that reacted with the
anti-C6 antibody, albeit weakly in some cases
(Fig. 1B). This result also illustrates the antigenic
conservation of IR6.

View larger version (83K):
[in this window]
[in a new window]
|
FIG. 1.
Epitopes of the C-terminal invariable domain differ
among strains and genospecies of B. burgdorferi sensu
lato. Whole-cell lysates of strains B31, Sh-2-82, NT1, JD1, N40, IP90,
G1, G25, NBS23A, NBS16, J1, and P/Gau were separated by
SDS-polyacrylamide gel electrophoresis and transferred onto
nitrocellulose. Blots were reacted with either mouse anti-Ct antiserum
(A) or rabbit anti-C6 antiserum (B). Molecular masses (MW)
are depicted in kilodaltons (kDa) at the left of the figure.
|
|
The C-terminal invariable domain is immunodominant during a
B. burgdorferi infection but antigenically scarcely
conserved among strains of B. burgdorferi sensu
lato.
In a previous study, all four mice that were infected with
B. burgdorferi B31 showed a strong antibody response to the
C-terminal invariable domain (22). To further determine if
this domain is immunodominant during B. burgdorferi
infection, serum specimens from seven monkeys and six mice that were
infected with B31 spirochetes by tick inoculation were tested. A strong
antibody response to the C-terminal invariable domain was detected in
all of the animals (Fig. 2, monkeys L379,
L452, L453, L457, L549, M021, and M581, and
3, mice 184, 191, 194, 196, 408, and 409)
as assessed by the Ct ELISA. These results indicated that the
C-terminal invariable domain was immunodominant during B. burgdorferi infection regardless of host species.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
The C-terminal invariable domain is immunodominant but
is not antigenically conserved among strains of B.
burgdorferi in monkeys. Monkeys were infected with B.
burgdorferi strain B31 (monkeys L379, L452, L453, L457, L549,
M021, and M581), JD1 (monkeys J200, J831, K205, K216, K383, and L131)
or NT1 (monkeys P285, P607, R383, R454, R817, and V591) by tick bite.
Levels of antibody to IR6 and the C-terminal invariable
domain were assessed using C6 and Ct ELISAs, respectively.
The cutoff value (0.113) was based on the mean OD plus 3 standard
deviations of 10 monkey prebleeds when the two peptides were separately
used as an ELISA antigen.
|
|

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 3.
The C-terminal invariable domain is immunodominant, but
its antigenic conservation is limited among strains of B.
burgdorferi sensu lato in mice. Eighteen C3H mice were infected
either with strain B31 (184, 191, 194, 196, 408, and 409) by tick
inoculation or with strain N40 (Q53 and Q59), JD1 (A77, A78, A79, A80,
and A81), or Sh-2-82 (219, 220, 224, 288, and 289) by needle
inoculation. Fourteen BALB/c mice were inoculated by either Malonne
(M50, M52, M54, M56, M58, M62, and M64) or Neuchâtel (N57,
N59, N63, N65, N67, N69, and N71) ticks. Levels of antibody to
IR6 and the C-terminal invariable domains were assessed
using C6 and Ct ELISAs, respectively. The cutoff value
(0.120) was based on the mean OD plus 3 standard deviations of 10 mouse
prebleeds when the two peptides were separately used as an ELISA
antigen.
|
|
To determine if the C-terminal invariable domain is antigenically
conserved among strains of B. burgdorferi sensu lato, serum specimens from monkeys and mice that were infected with spirochetal strains other than B31 either by needle inoculation or tick bite were
assessed. None of the 12 monkeys that were infected with either JD1
(monkeys J200, J831, K205, K216, K383, and L131) or NT1 spirochetes
(monkeys P285, P607, R383, R454, R817, and V591) produced a detectable
antibody response to the Ct peptide (Fig. 2). In contrast, antibody to
IR6 was detected in all animals by C6 ELISA (Fig. 2). This latter result ruled out
the possibility that the spirochetes infecting these animals did not
express VlsE or had lost lp28-1, the plasmid that carries the
vlsE locus. Since the C-terminal invariable domain appears
to be immunodominant, the negative Ct ELISA results are most likely due
to lack of antigenic conservation of the C-terminal invariable domain
expressed by these strains.
Slightly different results were obtained with mice. The two mice that
were infected with strain N40 (mice Q53 and Q59), one of the five mice
that were infected with strain JD1 (mice A77, A78, A79, A80, and A81)
and one of the five mice that were infected with strain Sh-2-82 (mice
219, 220, 224, 288, and 289) produced a significant antibody response
to the Ct peptide (Fig. 3). Five of the seven mice that were infected
by Malonne ticks (mice M50, M52, M54, M56, M58, M62, and M64) contained
a high level of antibody to Ct, while only two of the seven mice
infected with Neuchâtel ticks (mice N57, N59, N63, N65, N67, N69,
and N71) produced a weak antibody response to this peptide (Fig. 3).
Strong antibody responses to IR6 in all of the 32 mice indicated, as with monkeys, that VlsE was expressed (Fig. 3).
Since the C-terminal invariable domain is immunodominant, antibody to
this domain should have been elicited in all of the infected mice.
Therefore, failure to detect anti-Ct antibody in most of the
infected mice (only 11 of the 26 infected mice responded to Ct) is
likely due to lack of antigenic conservation of the C-terminal
invariable domain.
Serodiagnostic value of the Ct peptide for both canine and
human Lyme disease is limited.
The diagnostic sensitivity
of the Ct peptide ELISA was compared with that of the
C6 ELISA in both dogs and humans. Twenty-six of
the 33 serum samples from dogs that were infected with field-caught ticks (dogs 1 to 33) and only 5 of the 18 serum samples from clinically diagnosed dogs (samples 40 to 57) contained detectable anti-Ct antibody, while all of these 51 specimens were
anti-C6 antibody positive (Fig.
4). These results indicate that the
C6 ELISA performs better than the Ct ELISA as a
diagnostic tool for dogs. The 33 serum specimens were collected at 7 to
8 weeks after dogs were experimentally infected with B. burgdorferi. In a previous study, the C6
ELISA yielded 100% sensitivity with sera from experimentally infected
dogs as early as 4 weeks postinfection and 32% sensitivity (7 of 22)
with sera collected at 3 weeks postinfection (21). To
determine if the Ct ELISA is able to detect early infections, 30 dog
serum samples that were collected at 2 to 3 weeks after experimental
inoculation via ticks were analyzed using the Ct ELISA. No positive
results were obtained (data not shown). Thus, the Ct ELISA did not
improve diagnostic sensitivity with respect to the
C6 ELISA in early canine Lyme disease.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 4.
Comparison of peptides C6 and Ct for
detection of B. burgdorferi infection in dogs.
Thirty-three dogs (dogs 1 to 33) were infected by tick inoculation.
Eighteen sera (sera 40 to 57) were collected from dogs clinically
diagnosed with Lyme disease. Antibody levels to IR6 and the
C-terminal invariable domain were assessed using C6 and Ct
ELISAs, respectively. The cutoff value (OD = 0.113) was defined as
the mean OD plus 3 standard deviations of 10 serum samples from healthy
dogs from an area where Lyme disease is not endemic, when the two
peptides were separately used as ELISA antigens.
|
|
To compare the performance of these two peptides in the serodiagnosis
of human Lyme disease, 85 serum samples collected from both American
and European patients with early or late Lyme disease were analyzed.
All of the serum specimens were positive by the C6 ELISA regardless of their geographic origins
(Table 1).
Although most of the American sera (57 of 64) were also positive by the Ct ELISA, only 12 of the 21 European specimens contained detectable anti-Ct antibody (Table 1). To determine if the Ct ELISA is able to
detect an earlier infection, 32 sera that were collected from both
American and European patients with early B. burgdorferi infection were analyzed by the Ct ELISA. All of the 32 samples were
negative by the C6 ELISA. Two of the 24 American
specimens were positive, while none of the 8 European specimens was
positive by the Ct ELISA (data not shown).
 |
DISCUSSION |
Although VlsE is a variable antigen, its C-terminal invariable
domain accounts for 15% of the entire molecule's length and remains
unchanged during antigenic variation (32). Initial data indicated that the sequence conservation of this domain might be
limited among strains of B. burgdorferi sensu stricto
(12) and that the domain is antigenic in mice during
B. burgdorferi infection (22). However, nothing
was known about its antigenic conservation and its diagnostic value in
Lyme disease serology.
To initially assess epitope conservation of the C-terminal
invariable domain, whole-cell extracts of spirochetes belonging to 12 different strains that represent the three pathogenic genospecies of B. burgdorferi sensu lato were reacted with mouse anti-Ct
antiserum. This antiserum was generated by immunizing animals with the
Ct-KLH conjugate; the Ct peptide reproduced the sequence of the
C-terminal invariable domain of VlsE expressed by the B31 B. burgdorferi strain (32). The anti-Ct antibody
recognized only the VlsE antigen extracted from B31 spirochetes but not
others, indicating that epitopes of the C-terminal invariable
domain expressed by different strains are not the same. Antigenic
conservation may be more stringent than sequence conservation in that a
single amino acid substitution, a minimal sequence alteration, may
destroy or diminish antigenicity of an epitope. Nonetheless, our
results show that the C-terminal domain sequences of the VlsE of the 11 strains tested are not the same as that of B31. What our experiment
cannot ascertain is to what extent the antigenic differences
observed are reflected by sequence differences. The mouse anti-Ct
antibody that we generated may be directed to a single epitope
among the many that are likely present in the 51 amino acids of Ct.
Thus, the absence of antigenicity could be brought about by relatively
small sequence differences. Moreover, it is formally possible
although unlikely that the 11 strains that we compared all have
identical C-terminal VlsE sequences that differ from that of B31.
To determine if the C-terminal invariable domain is immunodominant
during a natural infection, sera from seven monkeys that were infected
with B31 spirochetes via ticks were analyzed for an antibody response
with the Ct ELISA. To further assess the antigenic conservation of this
domain among strains of B. burgdorferi sensu lato, anti-Ct
antibody was quantified in serum specimens obtained from an additional
12 monkeys that were infected with spirochetes from strains other than
B31. Only the B31-infected monkeys produced a significant level of
antibody to Ct. These results suggested that the C-terminal invariable
domain is immunodominant in monkeys but is not antigenically conserved
among strains of B. burgdorferi during infection in this
host species. The strong immunogenicity or immunodominance of the
C-terminal invariable domain of VlsE during infection was further
demonstrated by the high anti-Ct antibody levels quantified in six of
six mice infected with B31 spirochetes.
The response was less uniform in mice than in monkeys. Some of the mice
that were infected with spirochetes from strains other than B31
responded to Ct, albeit weakly in some cases, whereas others did not.
We had already determined that the response of mice and dogs to VlsE
differed from that of both humans and nonhuman primates (17,
21). For instance, IR2 and
IR4 are antigenic in both mice and dogs but not
in humans and monkeys. In addition, the two primate species respond to
a single epitope within IR6, but mice may
recognize multiple epitopes of this region (19). The
51-mer C-terminal invariable domain might contain several epitopes. Some of them might be more antigenically conserved than others among the strains of B. burgdorferi sensu lato.
Monkeys probably only respond to less antigenically conserved regions, while mice can produce antibody to more conserved ones.
The C6 peptide ELISA has been shown to yield
nearly 100% diagnostic sensitivity with serum specimens from humans
(including American and European patients) with late Lyme disease
(18, 20) and dogs with B. burgdorferi infection
(21). In this study, the diagnostic performance of
peptides C6 and Ct was compared with both human
and dog serum samples. Although most of the dogs (26 of 33) that were
experimentally infected by tick inoculation had a detectable anti-Ct
response, only 5 of 18 specimens from clinically diagnosed animals were
positive by the Ct ELISA. This difference may have resulted from a more
disparate geographic distribution of the latter samples, as the ticks
that were used to experimentally infect the dogs probably were
collected in a more constrained region of the state of New York than
that from which the clinically diagnosed samples originated. The
spirochetes that were carried by the ticks may be genetically more
related to strain B31 than are the spirochetes that infected the
clinically diagnosed dogs. This interpretation also applies to the
results obtained with human samples. A high proportion of the American patients with Lyme disease (57 of 64) had a detectable anti-Ct antibody
response, while only 12 of the 21 European specimens were positive by
the Ct ELISA. The American specimens were collected mainly from East
Coast regions of the United States.
The C6 ELISA yielded sensitivities of 85% (117 of 138) for American patients and 83% (20 of 24) for European patients
with early Lyme disease (including both acute and convalescent phases) (18, 20). In dogs, 7 of 22 (32%) B. burgdorferi infections were detected as early as 3 weeks and 100%
(33 of 33) sensitivity was achieved after 4 weeks postinfection by the
C6 ELISA (21). In this study, to
assess if the Ct ELISA could improve sensitivity for detecting earlier
B. burgdorferi infection, 22 canine serum specimens that
were collected at 2 to 3 weeks postinfection and 32 human specimens
that were collected from both American and European patients at either
the acute or convalescent phase were analyzed by this assay. All these
specimens were negative by the C6 ELISA. None of
the dog or European human samples had a detectable anti-Ct antibody
response, and only 2 of the 24 American specimens were positive by the
Ct ELISA. Hence, overall, no significant sensitivity improvement was
afforded. So far, the C6 peptide, which is based
on the sequence of IR6 of the IP90 strain of
B. garinii, is the best single antigen for serodiagnosis of
Lyme disease in both the United States and Europe (18,
20). Moreover, in view of the limited conservation of the
antigenicity of the C-terminal domain of VlsE, it is possible that the
diagnostic performance of this molecule may hinge entirely upon that of
IR6. It should be noted, however, that the
antigenic contribution of the N-terminal domain has not been determined
as yet.
 |
ACKNOWLEDGMENTS |
We thank Lise Gern (University of Neuchâtel,
Neuchâtel, Switzerland), Vincent Weynants (GlaxoSmithKline
Biologicals, Rixensart, Belgium), Reinhard Straubinger
(Universität Leipzig, Leipzig, Germany), Richard Jacobson
(Cornell University, Ithaca, N.Y.), Amy Grooters (Louisiana State
University, Baton Rouge, La.), Martin Schriefer (Centers for Disease
Control and Prevention, Fort Collins, Colo.), Allen Steere (Tufts
University, Boston, Mass.), Adriana Marques (National Institutes of
Health, Bethesda, Md.), Elisabeth Aberer (University of Graz, Graz,
Austria), and Marina Cinco (Università Trieste, Trieste,
Italy) for providing serum samples.
This work was supported in part by grant RR00164 from NCRR, NIH.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Tulane Regional
Primate Research Center, Tulane University Health Sciences Center, 18703 Three Rivers Rd., Covington, LA 70433. Phone: (504) 871-6221. Fax: (504) 871-6390. E-mail: philipp{at}tpc.tulane.edu.
Editor:
R. N. Moore
 |
REFERENCES |
| 1.
|
Barbet, A. F., and T. C. McGuire.
1978.
Crossreacting determinants in variant-specific surface antigens of African trypanosomes.
Proc. Natl. Acad. Sci. USA
75:1989-1993[Abstract/Free Full Text].
|
| 2.
|
Barony, G., and R. B. Merrifield.
1980.
The peptides: analysis, synthesis, and biology, p. 3-285.
Academic Press, New York, N.Y.
|
| 3.
|
Barstad, P. A.,
J. E. Coligan,
M. G. Raum, and A. G. Barbour.
1985.
Variable major proteins of Borrelia hermsii, epitope mapping and partial sequence analysis of CNBr peptides.
J. Exp. Med.
161:1302-1314[Abstract/Free Full Text].
|
| 4.
|
Borst, P.
1991.
Molecular genetics of antigenic variation.
Immunol. Today
12:A29-A33[CrossRef][Medline].
|
| 5.
|
Borst, P., and G. A. M. Cross.
1982.
Molecular basis for trypanosome antigenic variation.
Cell
29:291-303[CrossRef][Medline].
|
| 6.
|
Cross, G. A. M.
1979.
Crossreacting determinants in the C-terminal region of trypanosome variant surface antigens.
Nature
277:310-312[CrossRef][Medline].
|
| 7.
|
Forest, K. T.,
S. L Bernstein,
E. D. Getzoff,
M. So,
G. Tribbick,
H. M. Geysen,
C. D. Deal, and J. A. Tainer.
1996.
Assembly and antigenicity of the Neisseria gonorrhoeae pilus mapped with antibodies.
Infect. Immun.
64:644-652[Abstract].
|
| 8.
|
French, D. M.,
T. F. McElwain,
T. C. McGuire, and G. H. Palmer.
1998.
Expression of Anaplasma marginale major surface protein 2 variants during persistent cyclic rickettsemia.
Infect. Immun.
66:1200-1207[Abstract/Free Full Text].
|
| 9.
|
French, D. M.,
W. C. Brown, and G. H. Palmer.
1999.
Emergence of Anaplasma marginale antigenic variants during persistent rickettsemia.
Infect. Immun.
67:5834-5840[Abstract/Free Full Text].
|
| 10.
|
Gern, L.,
U. E. Schaible, and M. M. Simon.
1993.
Mode of inoculation of the Lyme disease agent Borrelia burgdorferi influences infection and immune responses in inbred strains of mice.
J. Infect. Dis.
167:971-975[Medline].
|
| 11.
|
Hagblom, P.,
E. Segal,
E. Billyard, and M. So.
1985.
Intragenic recombination leads to pilus antigenic variation in Neisseria gonorrhoeae.
Nature
315:156-168[CrossRef][Medline].
|
| 12.
|
Iyer, R.,
J. M. Hardham,
G. P. Wormser,
I. Schwartz, and S. J. Norris.
2000.
Conservation and heterogeneity of vlsE among human and tick isolates of Borrelia burgdorferi.
Infect. Immun.
68:1714-1718[Abstract/Free Full Text].
|
| 13.
|
Kahl, O.,
L. Gern,
J. S. Gray,
E. C. Guy,
F. Jongejan,
F. Kirstein,
K. Kurtenbach,
S. G. Rijpkema, and G. Stanek.
1998.
Detection of Borrelia burgdorferi sensu lato in ticks: immunofluorescence assay versus polymerase chain reaction.
Zentbl. Bakteriol.
287:205-210.
|
| 14.
|
Kawabata, H.,
F. Myouga,
Y. Inagaki,
N. Murai, and H. Watanabe.
1998.
Genetic and immunological analyses of Vls (VMP-like sequences) of Borrelia burgdorferi.
Microb. Pathog.
24:155-166[CrossRef][Medline].
|
| 15.
|
Lawrenz, B. M.,
J. M. Hardham,
R. T. Owens,
J. Nowakowski,
A. C. Steere,
G. P. Wormser, and S. J. Norris.
1999.
Human antibody responses to VlsE antigenic variable protein of Borrelia burgdorferi.
J. Clin. Microbiol.
37:3997-4004[Abstract/Free Full Text].
|
| 16.
|
Liang, F. T.,
A. L. Alvarez,
Y. Gu,
J. M. Nowling,
R. Ramamoorthy, and M. T. Philipp.
1999.
An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi.
J. Immunol.
163:5566-5573[Abstract/Free Full Text].
|
| 17.
|
Liang, F. T., and M. T. Philipp.
1999.
Analysis of antibody response to invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi.
Infect. Immun.
67:6702-6706[Abstract/Free Full Text].
|
| 18.
|
Liang, F. T.,
A. C. Steere,
A. R. Marques,
B. J. B. Johnson,
J. N. Miller, and M. T. Philipp.
1999.
Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE.
J. Clin. Microbiol.
37:3990-3996[Abstract/Free Full Text].
|
| 19.
|
Liang, F. T., and M. T. Philipp.
2000.
Epitope mapping of the immunodominant invariable region of VlsE, the variable surface antigen of Borrelia burgdorferi.
Infect. Immun.
68:2349-2352[Abstract/Free Full Text].
|
| 20.
|
Liang, F. T.,
E. Aberer,
M. Cinco,
L. Gern,
C. M. Hu,
Y. N. Lobet,
M. Ruscio,
P. E. Voet, Jr.,
V. E. Weynants, and M. T. Philipp.
2000.
Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL.
J. Infect. Dis.
182:1455-1462[CrossRef][Medline].
|
| 21.
|
Liang, F. T.,
R. H. Jacobson,
R. K. Straubinger,
A. Grooters, and M. T. Philipp.
2000.
Characterization of a Borrelia burgdorferi VlsE invariable region useful for canine Lyme disease serodiagnosis by enzyme-linked immunosorbent assay.
J. Clin. Microbiol.
38:4160-4166[Abstract/Free Full Text].
|
| 22.
|
Liang, F. T.,
M. B. Jacobs, and M. T. Philipp.
2001.
C-terminal invariable domain of VlsE may not serve as target for protective immune response against Borrelia burgdorferi.
Infect. Immun.
69:1337-1343[Abstract/Free Full Text].
|
| 23.
|
Meier, J. T.,
M. I. Simon, and A. G. Barbour.
1985.
Antigenic variation is associated with DNA rearrangements in a relapsing fever Borrelia.
Cell
41:403-409[CrossRef][Medline].
|
| 24.
|
Palmer, G. H.,
W. C. Brown, and F. R. Rurangirwa.
2000.
Antigenic variation in the persistence and transmission of the ehrlichia Anaplasma marginale.
Microbes Infect.
2:167-176[CrossRef][Medline].
|
| 25.
|
Philipp, T. M.,
M. K. Aydintug,
R. P. Bohm, Jr.,
F. B. Cogswell,
V. A. Dennis,
H. N. Lanners,
R. C. Lowrie, Jr.,
E. D. Roberts,
M. D. Conway,
M. Karaçorlu,
G. A. Peyman,
D. J. Gubler,
B. J. B. Johnson,
J. Piesman, and Y. Gu.
1993.
Early and early disseminated phases of Lyme disease in the rhesus monkey: a model for infection in humans.
Infect. Immun.
61:3047-3059[Abstract/Free Full Text].
|
| 26.
|
Postic, D.,
M. V. Assous,
P. A. D. Grimont, and G. Baranton.
1994.
Diversity of Borrelia burgdorferi sensu lato evidenced by restriction fragment length polymorphism of rrf (5S)-rrl (23S) intergenic spacer amplicons.
Int. J. Syst. Bacteriol.
44:743-752[Abstract/Free Full Text].
|
| 27.
|
Rothbard, J. B.,
R. Fernandez, and G. K. Schoolnik.
1984.
Strain-specific and common epitopes of gonococcal pili.
J. Exp. Med.
160:208-221[Abstract/Free Full Text].
|
| 28.
|
Stoenner, H. G.,
T. Dodd, and C. Larsen.
1982.
Antigenic variation of Borrelia hermsii.
J. Exp. Med.
156:1297-1311[Abstract/Free Full Text].
|
| 29.
|
Straubinger, R. K.,
A. F. Straubinger,
B. A. Summers, and R. H. Jacobson.
2000.
Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study.
J. Infect. Dis.
181:1069-1081[CrossRef][Medline].
|
| 30.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 31.
|
Van der Ploeg, L. H. T.,
K. Gottesdiener, and M. G. S. Lee.
1992.
Antigenic variation in African trypanosomes.
Trends Genet.
8:452-457[Medline].
|
| 32.
|
Zhang, J. R.,
J. M. Hardham,
A. G. Barbour, and S. J. Norris.
1997.
Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes.
Cell
89:275-285[CrossRef][Medline].
|
| 33.
|
Zhang, J. R., and S. J. Norris.
1998.
Genetic variation of the Borrelia burgdorferi gene vlsE involves cassette-specific, segmental gene conversion.
Infect. Immun.
66:3698-3704[Abstract/Free Full Text].
|
| 34.
|
Zhang, J. R., and S. J. Norris.
1998.
Kinetics and in vivo induction of genetic variation of vlsE in Borrelia burgdorferi.
Infect. Immun.
66:3689-3697[Abstract/Free Full Text].
|
Infection and Immunity, May 2001, p. 3224-3231, Vol. 69, No. 5
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.3224-3231.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Embers, M. E., Jacobs, M. B., Johnson, B. J. B., Philipp, M. T.
(2007). Dominant Epitopes of the C6 Diagnostic Peptide of Borrelia burgdorferi Are Largely Inaccessible to Antibody on the Parent VlsE Molecule. CVI
14: 931-936
[Abstract]
[Full Text]
-
Embers, M. E., Wormser, G. P., Schwartz, I., Martin, D. S., Philipp, M. T.
(2007). Borrelia burgdorferi Spirochetes That Harbor Only a Portion of the lp28-1 Plasmid Elicit Antibody Responses Detectable with the C6 Test for Lyme Disease. CVI
14: 90-93
[Abstract]
[Full Text]
-
Magnarelli, L. A., Stafford, K. C. III, IJdo, J. W., Fikrig, E.
(2006). ANTIBODIES TO WHOLE-CELL OR RECOMBINANT ANTIGENS OF BORRELIA BURGDORFERI, ANAPLASMA PHAGOCYTOPHILUM, AND BABESIA MICROTI IN WHITE-FOOTED MICE. J Wildl Dis
42: 732-738
[Abstract]
[Full Text]
-
Hamby, C. V., Llibre, M., Utpat, S., Wormser, G. P.
(2005). Use of Peptide Library Screening To Detect a Previously Unknown Linear Diagnostic Epitope: Proof of Principle by Use of Lyme Disease Sera. CVI
12: 801-807
[Abstract]
[Full Text]
-
Liang, F. T., Yan, J., Mbow, M. L., Sviat, S. L., Gilmore, R. D., Mamula, M., Fikrig, E.
(2004). Borrelia burgdorferi Changes Its Surface Antigenic Expression in Response to Host Immune Responses. Infect. Immun.
72: 5759-5767
[Abstract]
[Full Text]
-
O'Connor, T. P., Esty, K. J., Hanscom, J. L., Shields, P., Philipp, M. T.
(2004). Dogs Vaccinated with Common Lyme Disease Vaccines Do Not Respond to IR6, the Conserved Immunodominant Region of the VlsE Surface Protein of Borrelia burgdorferi. CVI
11: 458-462
[Abstract]
[Full Text]
-
Magnarelli, L. A., IJdo, J. W., Ramakrishnan, U., Henderson, D. W., Stafford, K. C. III, Fikrig, E.
(2004). USE OF RECOMBINANT ANTIGENS OF BORRELIA BURGDORFERI AND ANAPLASMA PHAGOCYTOPHILUM IN ENZYME-LINKED IMMUNOSORBENT ASSAYS TO DETECT ANTIBODIES IN WHITE-TAILED DEER. J Wildl Dis
40: 249-258
[Abstract]
[Full Text]
-
Schulte-Spechtel, U., Lehnert, G., Liegl, G., Fingerle, V., Heimerl, C., Johnson, B. J. B., Wilske, B.
(2003). Significant Improvement of the Recombinant Borrelia-Specific Immunoglobulin G Immunoblot Test by Addition of VlsE and a DbpA Homologue Derived from Borrelia garinii for Diagnosis of Early Neuroborreliosis. J. Clin. Microbiol.
41: 1299-1303
[Abstract]
[Full Text]
-
Jespersen, D. J., Smith, T. F., Rosenblatt, J. E., Cockerill III, F. R.
(2002). Comparison of the Borrelia DotBlot G, MarDx, and VIDAS Enzyme Immunoassays for Detecting Immunoglobulin G Antibodies to Borrelia burgdorferi in Human Serum. J. Clin. Microbiol.
40: 4782-4784
[Abstract]
[Full Text]
-
McDowell, J. V., Sung, S.-Y., Hu, L. T., Marconi, R. T.
(2002). Evidence That the Variable Regions of the Central Domain of VlsE Are Antigenic during Infection with Lyme Disease Spirochetes. Infect. Immun.
70: 4196-4203
[Abstract]
[Full Text]
-
MAGNARELLI, L. A., LAWRENZ, M., NORRIS, S. J., FIKRIG, E.
(2002). Comparative reactivity of human sera to recombinant VlsE and other Borrelia burgdorferi antigens in class-specific enzyme-linked immunosorbent assays for Lyme borreliosis. J Med Microbiol
51: 649-655
[Abstract]
[Full Text]
-
Eicken, C., Sharma, V., Klabunde, T., Lawrenz, M. B., Hardham, J. M., Norris, S. J., Sacchettini, J. C.
(2002). Crystal Structure of Lyme Disease Variable Surface Antigen VlsE of Borrelia burgdorferi. J. Biol. Chem.
277: 21691-21696
[Abstract]
[Full Text]
-
Liang, F. T., Jacobs, M. B., Bowers, L. C., Philipp, M. T.
(2002). An Immune Evasion Mechanism for Spirochetal Persistence in Lyme Borreliosis. JEM
195: 415-422
[Abstract]
[Full Text]
-
Indest, K. J., Howell, J. K., Jacobs, M. B., Scholl-Meeker, D., Norris, S. J., Philipp, M. T.
(2001). Analysis of Borrelia burgdorferivlsE Gene Expression and Recombination in the Tick Vector. Infect. Immun.
69: 7083-7090
[Abstract]
[Full Text]